---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-205839"
form_type: "8-K"
ticker: "SCLX"
cik: "0001820190"
company_name: "Scilex Holding Co"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:30:50.488855+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Scilex subsidiary to sell ACEA Pharma to Phoenix Asia for $1B in stock, owning 82% post-close

## Summary
- ACEA Thera sells 100% of ACEA Pharma to Phoenix Asia for 100M shares at $10/share, valued at $1B.
- Post-close, ACEA Thera will own ~82% of Phoenix; Phoenix will be renamed ACEA Pharma.
- Boards of all parties unanimously approved; deal expected to close by end of Q2 2026.
- Closing conditions include HSR clearance, Nasdaq approval, and no material adverse effect.

## SEC filing metadata
- accession: 0001193125-26-205839
- form_type: 8-K
- ticker: SCLX
- cik: 0001820190
- company_name: Scilex Holding Co
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1820190/000119312526205839/0001193125-26-205839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1820190/000119312526205839/sclx-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-205839
- JSON: https://secwatch.observer/filing/0001193125-26-205839.json
- Plain text: https://secwatch.observer/filing/0001193125-26-205839.txt

## Source-grounded claims
- claim_id: c71085b47d8d6c6b8eb38919080c9ff2ec654028
  claim: Scilex Holding Co entered into ACEA-PHOE SAA with Phoenix Asia Holdings Limited valued at $1,000,000,000.00 (effective 2026-05-04).
  evidence_excerpt: On May 4, 2026, ACEA Therapeutics, Inc. (“ACEA Thera”), an indirect minority owned subsidiary of Scilex Holding Company (the “Company”), entered into a Stock Acquisition Agreement (the “ACEA-PHOE SAA”) with Phoenix Asia Holdings Limited, a company organized under the laws of the Cayman Islands (“Phoenix Asia”), and ACEA Pharma, Inc., a wholly owned subsidiary of ACEA Thera and an exempted company incorporated with limited liability in the Cayman Islands (“ACEA Pharma”), pursuant to which ACEA Thera agreed to transfer and sell, and Phoenix Asia agreed to purchase, 100% of the issued and outstanding shares of common stock of ACEA Pharma in exchange for the delivery to ACEA Thera of 100,000,000 newly-issued ordinary shares at $10.00 per share, par value $0.00001 per share, of Phoenix Asia (the “Stock Acquisition”), the value of which was as agreed by the parties to be $1,000,000,000.00.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1820190/000119312526205839/0001193125-26-205839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.